Takeda (NYSE:TAK) (4502.T) said on Monday that the European Commission approved Pfizer (NYSE:PFE) and the company’s antibody-drug conjugate, Adcetrix, in combination with a chemotherapy regimen in adults with newly diagnosed stage IIb Hodgkin lymphoma.
The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on April 25, 2025.
With the exception of the US and Canada, where Pfizer has commercialization rights, Takeda is in charge of Adcetris’ worldwide distribution.
This decision marks the second approval for an ADCETRIS-based combination regimen for frontline Hodgkin lymphoma, with six other approvals in the EU for the antibody-drug conjugate.
More on Takeda Pharmaceutical, Pfizer
- Pfizer’s Oral Obesity Drug Flop – A Symptom Of A Deeper Pipeline Problem
- Unlocking Pfizer’s Value: Cost Controls And Oncology Pipeline
- Investing In The Promising PD1/VEGF Bispecific – Pfizer And Instil Could Be Good Candidates
- FDA launches Elsa, an AI tool designed to accelerate agencywide operations
- Pfizer/Arvinas to seek FDA nod for jointly developed cancer therapy in H2